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Abstract 
Background: Non-steroidal anti-inflammatory drugs (NSAIDs) are widely prescribed in the community pharmacy. 
Their systemic administration has been related to significant adverse effects. The aim of this study was to evaluate 
the efficacy of topical NSAIDs in managing mild to moderate musculoskeletal pain versus systemic administration or 
combination of both routes.
Methods: This was a prospective observational study conducted in a large Lebanese community pharmacy over a 
period of 5 months in 302 patients. Participants were divided into three groups according to their route of administra-
tion of NSAIDs either topically, systemically or combination of both. During follow up period, degree of pain, efficacy 
of NSAID therapy, side effects, onset time and duration of pain relief reported by each patient were collected by the 
study investigators using specific formulated questionnaire. Degree of pain was assessed using the Numeric Rating 
Scale (NRS-11). The efficacy of NSAID therapy was defined as 50 % reduction or more in pain. The primary outcome 
was to assess the efficacy between groups. The secondary outcomes were onset time, duration of pain relief and side 
effects between the three groups.
Results: A total of 149 patients were enrolled in this study. 78 patients administered topical NSAIDs, 40 adminis-
tered systemic NSAIDs and 31 administered combination of both routes. Efficacy of NSAID therapy for all routes was 
reported in 132 participants (89 %) distributed as 64 in topical, 37 in systemic and 31 in combination. Bi-variate analy-
sis showed no significant difference in efficacy between topical versus systemic (p = 0.99) and topical versus com-
bination (p = 0.14). The mean onset of topical NSAIDs was significantly faster than systemic by 12.7 min (p < 0.05). 
The mean duration of pain relief of systemic NSAIDs was significantly longer than topical by 3 h (p < 0.05). Patients 
administered systemic NSAIDs (either alone or in combination) reported increase in blood pressure and gastric-upset 
8 and 38 cases, respectively.
Conclusion: There was no significant statistical difference between NSAIDs route’s of administration for the treat-
ment of mild to moderate musculoskeletal pain in Lebanese community pharmacy patients. Topical NSAIDs were fast 
in onset and effective in reducing pain with no significant adverse effects.
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Background
 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are 
among the most commonly used and effective medi-
cations to treat musculoskeletal conditions because of 
their anti-inflammatory and analgesic effects (Schnitzer 
et al. 2004; Mason et al. 2004; Zacher et al. 2001). Rasu 
et  al. (2013) study showed that NSAIDs were the most 
preferred and prescribed drugs for chronic pain in the 
U.S. Although NSAIDs are effective and widely used for 
musculoskeletal pain, their adverse effects have become 
more evident (Vonkeman and Van de Laar 2010). Many 
studies on systemic use of NSAIDs have shown high 
incidence of serious gastrointestinal and cardiovascu-
lar adverse events (Lanza et  al. 2009; Trelle et  al. 2011; 
RodrÃguez et al. 2008; Johnson et al. 1994; Traversa et al. 
1995). Topical NSAIDs were associated with lower side 
effects (Baraf et al. 2011); however their efficacy remains 
one of the most controversial issues in analgesia practice 
when compared to systemic NSAIDs (Klinge and Saw-
yer 2013). In the past 7 years, various updated guidelines 
such as National Institute for Health and Clinical Excel-
lence (NICE) (Conaghan et  al. 2008), European League 
Against Rheumatism (EULAR) (Smolen et al. 2010) and 
Osteoarthritis Research Society International (OARSI) 
(Zhang et  al. 2008) have included recommendations for 
the use of topical NSAIDs, particularly in patients con-
sidered at gastrointestinal or cardiovascular high risk. 
A meta-analysis evaluated 34 studies from 7688 adults 
with chronic musculoskeletal pain found that topical 
NSAIDs provided adequate pain relief, equivalent to oral 
NSAIDs for hand and knee osteoarthritis (Derry et  al. 
2012). Due to lower bioavailability and plasma concen-
tration compared to oral NSAID, topical administration 
provides local analgesia with lower incidence of systemic 
side effects (Stanos 2013; Miyatake et al. 2009). Neverthe-
less, the rate of local adverse effects is higher with topical 
NSAIDs, but they are reported to be minor self limited 
cutaneous reaction (Vaile and Davis 1998). According to 
our knowledge, there is a lack of sufficient evidence com-
paring oral to topical NSAIDs for the treatment of mus-
culoskeletal pain conditions in Lebanon. The purpose of 
this study was to evaluate the efficacy of topical NSAIDs 
in the treatment of mild to moderate musculoskeletal 
pain versus systemic or combination of both routes in 
Lebanese community pharmacy patients.
Methods
Study design
This was a prospective observational study conducted 
from January 2014 till end of May 2014 in a large commu-
nity pharmacy. All patients with a prescription of NSAID 
for the treatment of mild to moderate musculoskeletal 
pain were invited to participate in this study. Eligible 
patients were adults, had a prescription of NSAID to be 
administered either topically, systemically or in com-
bination of both routes and complaining from acute 
(6  weeks or less of symptoms), sub-acute (7–12  weeks 
of symptoms) or chronic (more than 12 weeks of symp-
toms) (Goertz et  al. 2012) mild (NRS 1–3) to moderate 
(NRS 4–6) musculoskeletal pain. Patients were excluded 
for the following reasons: severe musculoskeletal pain 
(NRS 7–10), cancer pain, headache, neuropathic pain, 
hypersensitivity to aspirin/NSAIDs or study participa-
tion refusal. The primary outcome of this study was to 
investigate the efficacy of NSAID therapy between vari-
ous routes of administration, whereas the secondary 
outcomes were to assess the onset time of pain relief 
(in min), duration of pain relief (in h) and side effects 
between different NSAID’s routes of administration.
Outcome measures
A structured questionnaire named “AD-23.16.14” was 
developed by the primary investigator and data were col-
lected directly from the participants during face to face 
interview for maximum of 20 min. The questionnaire was 
piloted before starting the data collection in patients that 
shares the same characteristics as this study population. 
The severity of pain was assessed by the primary inves-
tigator using the Numeric Rating Scale (NRS-11) (Mac-
Caffery and Beebe 1989). The efficacy measure of NSAID 
treatment was adopted from Moore et  al. (1998) study, 
and defined as at least 50 % reduction in pain throughout 
NSAID therapy.
The onset time of pain relief was defined as the time 
required after administration of NSAID for a response 
to be observed (Mosby 2012). The duration of pain relief 
was defined as the length of time that NSAID is effec-
tive (McGraw-Hill 2002). The side effects of different 
NSAIDs routes were divided into local (dryness, itching 
and stinging) and systemic (increase in blood pressure 
and gastric upset) and they were assessed during follow-
up dates by asking the patients to report any encoun-
tered side effects.
Study procedure
A total of 302 patients were initially screened and the 
following data were recorded for each patient at base-
line: patient’s age, gender, severity of pain, causes of 
pain, duration of pain (acute, sub-acute, chronic), site of 
pain, used analgesic in the last month, NSAID param-
eters (generic name, dose, frequency and dosage form), 
concomitant medications (anti-hypertensive, anti-dia-
betics and anti-lipidemics drugs), co-morbid diseases 
(hypertension, edema, ischemic heart disease, heart 
failure, peptic ulcer disease), history of previous gastro-
intestinal bleeding due to NSAIDs, and hypersensitivity 
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to NSAIDs/aspirin. Patients who met the inclusion cri-
teria were divided into three groups according to their 
NSAID’s route of administration including topical (gel, 
emulgel or difucrem), systemic (tablet, capsule, dispers-
ible tablet, suppository, or injection) and combination of 
both topical and systemic dosage forms.
Follow‑up
All patients were followed up by the primary investigator 
on Day 3, D6, D10, D14, Week 4, W8 and W12 through 
phone calls or scheduled pharmacy visits. Follow up was 
terminated when the patient discontinued the NSAID 
treatment for a certain reason (effective therapy, failure 
of therapy, intolerable side effects or therapy withdrawal). 
During follow-up dates, the primary investigator counse-
led the patients about proper use of NSAIDs in terms of 
dose, frequency, and route of administration. Degree of 
pain, efficacy of NSAID therapy, onset time of pain relief 
(estimated in min), duration of pain relief (estimated in 
h) and side effects (local and systemic) were reported 
by each patient and collected by the study investigators 
using specific formulated questionnaire “AD-23.16.14”. 
All patients were asked about their therapy satisfaction, 
medication adherence, and add-on analgesics other than 
NSAID. Total duration of therapy was also recorded at 
the end of the treatment.
Ethical considerations
Since our data collection methodology involves struc-
tured interview we obtained a signed informed con-
sent form before starting the study. The consent form 
explained that all data will be stored in the School of 
Pharmacy at the Lebanese International University 
(LIU). Copies of the informed consent were kept as data 
research records in LIU School of Pharmacy. All data that 
is collected from our study has the potential to be shared 
publically. Consequently, to maximize benefits and mini-
mize harm, investigators explained to all participants that 
any acquired information is to be treated with confiden-
tiality and published results are to be in aggregate form 
with no reference to names.
Statistical analysis
Descriptive statistics were used to describe patient char-
acteristics (frequencies and percentages for categorical 
variables), and mean (±SD) for continuous variables.
Bi-variate analysis and cross-tabulation were used 
to identify the significance between different routes of 
administration and the efficacy of NSAID treatment. One 
way analysis of variance (ANOVA) test was performed 
to identify whether there is difference in onset time and 
duration of pain relief among the 3 groups. Statistical 
significance was defined as p value <0.05. Statistical 
analyses were performed using the Statistical Package for 
Social Science (SPSS version 20.0 IBM).
Results
Patient’s characteristics
A total of 302 patients were initially screened, 153 patients 
(50.6  %) were excluded for the following reasons: severe 
musculoskeletal pain (20  %), neuropathic pain (12  %), 
headache (10  %), study participation refusal (8  %) and 
cancer pain (0.6 %). The remaining 149 (49.4 %) patients 
were enrolled and followed up in this study (Fig. 1).
Patient’s characteristics are shown in Table  1. 
Enrolled patients had a mean age of 40.7 ± 15.96 (mean 
years ± SD). From the total number of enrolled patients 
(n  =  149), 72 (48  %) participants were males and 77 
(52 %) were females. Majority of the patients (78 %) had 
moderate musculoskeletal pain.
Acute pain was the predominant duration of pain 
(67  %) followed by sub-acute (25  %) and chronic (8  %). 
Co-morbid diseases were reported by the participants at 
baseline such as hypertension (30 %), coronary artery dis-
ease (15 %), diabetes (8 %) and peptic ulcer disease (8 %). 
Consequently, anti-hypertensives (33  %), proton pump 
inhibitors (23 %), anti-lipidemics (16 %) and anti-diabet-
ics (9 %) were used by the participants.
Co-analgesics were used in addition to NSAID therapy 
by a total of 39 patients, of which 20 used muscle relax-
ants, 12 used acetaminophen and 7 used vitamin B com-
plex supplements.
Back pain was the most common site of musculoskel-
etal pain as reported by 42 patients (28  %), followed by 
shoulder (18 %), leg (10 %), neck (9 %), ankle (8 %), hand 
(4 %), knee (4 %), finger (3 %) and elbow pain (2 %).
A total of 76 patients (51  %) had a prescription of 
diclofenac, followed by ketoprofen 45 (30 %), aceclofenac 
37 (25  %), naproxen 18 (12  %), piroxicam 4 (2  %) and 
etoricoxib 1 (0.5 %).
Primary outcome
Efficacy of NSAID therapy among the three groups
The overall efficacy rate of NSAID therapy in mild to 
moderate musculoskeletal pain was reported in 132 
patient out of 149 (89  %), distributed as 64 out of 78 
patients (82 %) in topical, 37 out of 40 patients (92 %) in 
systemic, and 31 out of 31 patients (100 %) in combina-
tion group as shown in (Fig.  2). Bi-variate analysis and 
cross-tabulation between different routes of adminis-
tration and the efficacy of NSAID treatment showed no 
significant difference in efficacy between topical versus 
systemic NSAID therapy (p value = 0.99) and topical ver-
sus NSAID combination therapy (p value = 0.14).
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Secondary outcomes
Onset time of pain relief
The mean onset time of pain relief was 17.3 min (±7.19 
SD) in the topical, 30 min (±10.3 SD) in the systemic and 
14.5 min (±3.87 SD) in the combination NSAID therapy 
group. Topical NSAIDs were significantly faster than 
systemic NSAIDs by 12.7 min with p value of the mean 
difference <0.05, but slower than in combination group 
by 2.8 min with p value = 0.28. The mean onset of pain 
relief in combination therapy was significantly faster than 
systemic by 15.5 min with p value of the mean difference 
<0.05 (Table 2).
D3 D6 D10 D14 W4 W8 W12
Topical 78 75 53 24 12 12 8
Systemic 40 39 23 3 2 0 0






















302 Patients were screened (100%)
149 Patients were eligible (49.4%)
153 Patients (50.6%) were excluded:
- 2 (0.6%) had cancer pain
- 24 (8%) refused to participate 
- 30 (10%) had headache
- 36 (12%) had neuropathic pain 
- 61 (20%) had severe   musculoskeletal 
pain























Fig. 1 Patient’s enrollment and follow-up. D day, W week. *Oral dosage forms included: tablet, capsule and dispersible tablet. 302 patients were ini-
tially screened. A total of 149 patients fulfilled the inclusion criteria and were enrolled and followed up through phone calls or scheduled pharmacy 
visits. Enrolled patients were divided into 3 groups according to the route of administration of their NSAID therapy. Degree of pain, efficacy of NSAID 
therapy, onset time of pain relief, duration of pain relief and side effects were assessed during follow-up dates. At the beginning all patients used 
NSAID for 3 days, afterward the number of patients decreased due to withdrawal of NSAID therapy for many reasons such as efficacy, lack of efficacy 
or adverse effects. Topical NSAID were used up to 12 weeks, systemic NSAID up to 4 weeks and combination of both routes up to 10 days
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Duration of pain relief
The mean duration of pain relief was 10  h (SD ±  3.74) 
in the systemic, 7 h (SD ± 3.46) in the topical and 11 h 
(±2.05 SD) in the combination NSAID therapy group. 
The mean duration of pain relief in systemic NSAIDs 
group was significantly longer than topical by 3  h with 
p value of the mean difference <0.05, but shorter than 
combination therapy by 1  h with p value of the mean 
difference  =  0.85. The mean duration of pain relief in 
combination group was significantly longer than topical 
group by 4  h with p value of the mean difference <0.05 
(Table 3).
Table 1 Patient’s characteristics
Characteristic Value
Age (years)
 Mean ± SD (range)—years 40.7 ± 15.96 (12–92)
Gender—no. (%)
 Male 72 (48)
 Female 77 (52)
Severity of pain—no. (%)
 Mild 33 (22)
 Moderate 116 (78)
Duration of pain—no. (%)
 Acute 100 (67)
 Sub-acute 37 (25)
 Chronic 12 (8)
Co-morbid diseases—no. (%)
 Hypertension 45 (30)
 CAD 23 (15)
 Diabetes 12 (8)
 PUD 12 (8)
Concomitant medications with NSAIDs—no. (%)
 Anti-hypertensives 49 (33)
 PPIs 34 (23)
 Anti-lipidemics 24 (16)
 Anti-diabetics 13 (9)
Concomitant analgesics with NSAIDs—no. (%)
 Muscle relaxant 20 (13.5)
  Topical group 7 (35)
  Systemic group 11(55)
  Combination group 2 (10)
 Acetaminophen 12 (12.5)
  Topical group 9 (75)
  Systemic group 1 (9)
  Combination group 2 (16)
 Vitamin B complex 7 (5)
  Topical group 0 (0)
  Systemic group 2 (29)
  Combination group 5 (71)
Sites of pain—no. (%)
 Back 42 (28)
 Shoulder 27 (18)
 Multiple sites* 21 (14)
 Legs 15 (10)
 Neck 13 (9)
 Ankle 12 (8)
 Hands 6 (4)
 Knees 6 (4)
 Fingers 4 (3)
 Elbow 3 (2)
Used NSAIDs agents—no. (%)
 Diclofenac 76 (51)
 Ketoprofen 45 (30)
Mild pain category included all patients with NRS 1–3; Moderate pain category 
included all patients with NRS 4–6
Acute pain: <6 weeks of symptoms, sub-acute pain: 7–12 weeks of symptoms, 
chronic pain: >12 weeks of symptoms
Anti-hypertensives included ACE inhibitors, CCBs, beta-blockers; PPIs included: 
omperazole, lanzoprazole and esomeprazole
Anti-lipidemics included statins and fibrates; anti-diabetics included 
sulfonylureas, metformin and insulin
Muscle relaxant included orphenadrine, chlorzoxazone and magnesium 
supplements
no. number, % percentage, SD standard deviation, CAD coronary artery disease, 
PUD peptic ulcer disease, PPI proton pump inhibitor
* Multiple sites variable is defined as involvement of 2 or more sites of pain
Table 1 continued
Characteristic Value
 Aceclofenac 37 (25)
 Naproxen 18 (12)
 Piroxicam 4 (2)







Distribuon of efficacy amoung the 3 groups
Topical Systemic Combinaon
Fig. 2 Overall efficacy of NSAID therapy and its distribution among 
the 3 groups. Overall efficacy of NSAID therapy is considered in all 
routes of administration (149 patients) when patients reported at 
least 50 % reduction of pain. Bi-variate analysis and cross-tabulation 
between different routes of administration and the efficacy of NSAID 
treatment were done to identify if there is a significant difference of 
efficacy when distributed among the 3 groups. No significant differ-
ence in efficacy between topical versus systemic (p value = 0.99) and 
topical versus combination of NSAID therapy (p value = 0.14)
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Side effects of NSAID therapy among the 3 groups
During the follow-up period, patients were asked by 
the primary investigator to report any encountered side 
effect. Adverse effects were divided into local and sys-
temic. Patients who administered systemic NSAIDs 
(either alone or in combination) reported increase in 
blood pressure and gastric-upset 8 and 38 cases respec-
tively. Whereas patients who administered topical 
NSAIDs reported mild transient local dermatological 
side effects, such as dryness, itching and stinging 2, 3 and 
2 cases respectively (Table 4).
Discussion
In this study, NSAIDs showed to be effective in the treat-
ment of mild to moderate musculoskeletal pain by 89 %. 
Roelofs et  al. (2008) study has also shown that NSAIDs 
were the mainstay treatment for acute and chronic mus-
culoskeletal pain.
The primary outcome of this study was to assess the 
efficacy of various NSAIDs routes in musculoskeletal 
pain. When efficacy of NSAID therapy was compared 
among the 3 groups, all patients (100 %) in the combina-
tion group had efficacy of NSAID therapy, followed by 
92 % in the systemic group and 82 % in the topical group. 
Bi-variate analysis and cross-tabulation showed no signif-
icant difference between the 3 groups in term of efficacy 
with a p values of 0.99 between topical versus systemic 
group and 0.14 between topical versus combination 
group. Three clinical trials, with 764 patients, compared 
topical NSAIDs with oral NSAIDs (diclofenac 100  mg 
daily in one trial and ibuprofen 1200  mg daily in two). 
The overall efficacy rate was similar for topical NSAIDs 
Table 2 Mean onset time of pain relief (estimated in minutes) among the 3 groups
Onset time of pain relief is defined as the time required after administration of NSAID for a response to be observed. Patients required a mean of 17.3 min to feel pain 
relief in topical NSAID group, 30 min in systemic NSAID group and 14.5 min in combination group
Mean onset difference among groups was calculated by subtracting mean onset of each 2 groups (i−j). One way analysis of variance (ANOVA) test was performed to 
assess if there is a significant difference in the mean onset time of pain relief among groups. Topical NSAIDSs were significantly faster than systemic by 12.7 min (p 
value <0.05, 95 % CI). Combination therapy was significantly faster than systemic by 15.5 min (p value <0.05, 95 % CI). Topical NSAIDs were insignificantly slower than 
combination group by 2.8 min (p value = 0.28, 95 % CI)
* The mean onset difference among groups is significant at p value <0.05 and 95 % confidence interval
Mean onset in each  
group (min)
“i”
Mean onset in each  
group (min) “j”
Mean onset difference among  
groups (min): “i − j”
p value 95 % CI
Topical (17.3) Systemic (30) −12.7 0.001* −16.3631 −9.1241
Combination (14.5) 2.8 0.28 −1.1952 6.7080
Systemic (30) Topical (17.3) 12.7 0.001* 9.1241 16.3631
Combination (14.5) 15.5 0.001* 11.0464 19.9536
Combination (14.5) Topical (17.3) −2.8 0.28 −6.7080 1.1952
Systemic (30) −15.5 0.001* −19.9536 −11.0464
Table 3 Mean duration of pain relief (estimated in hours) among the 3 groups
Duration of pain relief is defined as the length of time that NSAID is still effective. Patients reported a mean of 7 h of pain relief in topical NSAID group, 10 h in systemic 
NSAID group and 11 h in combination NSAID group
Mean duration of pain relief difference among groups was calculated by subtracting mean duration of pain relief of each 2 groups (i − j). One way analysis of variance 
(ANOVA) test was performed to assess if there is a significant difference in the mean duration of pain relief among groups. Duration of pain relief in systemic NSAID 
group was significantly longer than topical NSAID group by 3 h (p value <0.05, 95 % CI). Duration of pain relief in combination group was significantly longer than 
topical group by 4 h (p value <0.05, 95 % CI) and insignificantly longer than systemic group by 1 h (p value = 0.85, 95 % CI)
* The mean duration of pain relief difference among groups is significant at p value <0.05 and 95 % confidence interval
Mean duration of pain  
relief in each group
“i”
Mean duration of pain  
relief in each group “j”
Mean duration of pain relief differ‑
ence among groups (hours) “i − j”
p value 95 % CI
Topical (7) Systemic (10) −3 0.001* −4.6341 −1.5172
Combination (11) −4 0.001* −5.6303 −2.2274
Systemic (10) Topical (7) 3 0.001* 1.5172 4.6341
Combination (11) −1 0.85 −2.7708 1.0644
Combination (11) Topical (7) 4 0.001* 2.2274 5.6303
Systemic (10) 1 0.85 −1.0644 2.7708
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(37 %) and oral NSAIDs (37 %) with no statistically sig-
nificant difference (Bookman et  al. 2004). These results 
were similar to that in our study. However, Curatolo and 
Bogduk (2001) used a pragmatic review of data provided 
by available systematic reviews and seminal controlled 
studies pertaining to the treatment of musculoskeletal 
pain concluded that NSAIDs have limited effectiveness in 
the treatment of musculoskeletal pain.
In this study, patients who administered the NSAID 
therapy for more than 4 weeks were in the topical group 
and had chronic musculoskeletal pain; during follow-up 
dates, these participants reported that they were satis-
fied with the results of the topical NSAID till the end of 
the study. Similarly, Underwood et  al. (2008) compared 
topical versus oral NSAIDs in chronic knee pain and con-
cluded that topical NSAIDs are as effective as oral in knee 
pain for 12  months; this reflects that topical NSAIDs 
could retain their efficacy when used chronically.
According to our knowledge, there are no other studies 
that investigated the onset time of pain relief and dura-
tion of pain relief of NSAID therapy in community phar-
macy patients. This study showed that topical NSAIDs 
were significantly faster in onset (mean  =  17.3  min) 
compared to systemic therapy (mean  =  30  min), this 
could be due to the direct and local effects of topical dos-
age form on the affected area. Duration of pain relief in 
systemic NSAIDs group (mean = 10 h) was significantly 
longer than topical NSAIDs group (mean  =  7  h) this 
could be explained by the accumulation of NSAID in the 
synovial fluids and soft tissues, that would increase the 
time to clear the drug from these sites. What is important 
about combination of both NSAIDs routes that it com-
bined the fast onset of topical and the long duration of 
pain relief of systemic NSAIDs and ended up with a rem-
edy of rapid onset (mean = 15 min) and extended dura-
tion of action (mean = 11 h).
The addition of other analgesics like acetaminophen, 
muscle relaxants and vitamin B complex were reported. 
These co-analgesics interfered with the efficacy of the 
NSAID treatment and could be considered as confound-
ing variables. It was noted that vitamin B complex and 
muscle relaxants were frequently administered in the sys-
temic group, whereas acetaminophen was mainly taken 
in the topical NSAIDs group.
In our study, systemic side effects such as increased 
blood pressure and gastrointestinal upset were reported 
in 8 and 38 participants respectively, these participants 
were taking NSAIDs systemically either alone or in com-
bination. Surprisingly, the rate of these systemic side 
effects was lower in the combination group compared 
to systemic group; this could be explained by the lower 
doses and frequencies of the used systemic NSAIDs 
when combined with the topical NSAIDs. A study done 
by Miyatake et  al. (2009) showed that plasma levels 
resulting from topical and oral applications of diclofenac 
were comparable; however, after topical application the 
concentration levels were higher in the muscle and lower 
in the synovial tissues of osteoarthritis patients compared 
with orally treated patients. Conversely, a comprehen-
sive review article done by Klinge and Sawyer (2013) in 
which topical NSAIDs and oral NSAIDs were compared 
in the treatment of both acute and chronic musculoskel-
etal injury, the authors concluded that caution should be 
exercised with the use of both topical and oral NSAIDs, 
particularly in patients with previous adverse reactions to 
NSAIDs.
We found that most of the patients had applied topi-
cal NSAIDs for a total of 10 days, those patients reported 
high rates of efficacy and mild self limited local adverse 
events described as dryness, itching and stinging. 
Similarly, Baer et  al. (2005) and Bookman et  al. (2004) 
reported dry skin as the most common local adverse 
event of the topical NSAID therapy. Additionally, sev-
eral studies have compared topical with oral NSAIDs 
and concluded that topical NSAIDs were effective and 
safe in treating acute painful conditions for one week, 
Table 4 Reported systemic and  local side effects in  the 3 
groups
Local and systemic side effects were assessed during follow-up dates. Gastric 
upset was characterized by epigastric pain, heartburn, stomach discomfort, 
bloating, nausea and vomiting
no Number of enrolled patients, SE side effects
Systemic SE
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and patients preferred to use topical NSAIDs as gastro-
intestinal adverse events limited the use of oral NSAIDs 
(Dickson 1991; Rother et  al. 2007; Tugwell et  al. 2004; 
Mason et al. 2004; Derry et al. 2015). Accordingly, topi-
cal NSAIDs could be a reasonable option to treat mild to 
moderate musculoskeletal pain as it provides good effi-
cacy with no systemic side effects, especially in patients 
with hypertension and gastrointestinal diseases.
Strengths and limitations
This is the first descriptive study that was specifically 
designed to assess the efficacy, onset time of pain relief 
and duration of pain relief of topical, systemic or combi-
nation of both routes of NSAIDs in Lebanese community 
pharmacy patients.
One of the major limitations was the patient’s assess-
ment of pain, since it is a personal feeling and it could vary 
between subjects. Another limitation of the study was the 
use of different NSAIDs agents for a short period of time; 
consequently many long term outcomes couldn’t be ana-
lyzed, this would explain the findings of few side effects 
of the NSAID therapy especially the systemic ones in the 
combination group. Baseline characteristics and classifica-
tion of the participants into three groups further decreased 
the sample size and affected the results. Additionally, the 
study was conducted at one community pharmacy in 
Lebanon which also justifies the small number of enrolled 
patients in this study and the inability of results generaliza-
tion. It would therefore be recommended to conduct addi-
tional studies including large sample size of patients taking 
NSAIDs for long period of time for the treatment of mus-
culoskeletal pain in all areas of Lebanon.
Conclusion
NSAIDs are the cornerstone of musculoskeletal pain 
treatment, but their systemic use may be limited in 
certain patients due to their potential adverse effects. 
According to our study, there was no significant statis-
tical difference of efficacy between topical, systemic or 
combination of both routes of NSAIDs in the treatment 
of mild to moderate musculoskeletal pain in Lebanese 
community pharmacy patients. Topical NSAIDs were 
fast in onset and effective in reducing pain with no sig-
nificant systemic adverse effects. Combination of topi-
cal and systemic NSAIDs routes showed faster onset and 
long duration of pain relief, but it was associated with 
systemic adverse effects. What remains unclear is the 
safety of NSAIDs combination of both routes. Addition-
ally it was uncertain if topical NSAIDs remain safe and 
retain their efficacy on the long term. Thereby, additional 
large-scale, long-term studies in patients with muscu-
loskeletal pain are needed to identify the role of topical 
NSAIDs when combined with oral NSAIDs.
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